Yonsei Med J.  2017 Jul;58(4):763-769. 10.3349/ymj.2017.58.4.763.

Combined Effect of Initial and Longitudinal Increases in γ-Glutamyltransferase on Incident Metabolic Syndrome: ARIRANG Study

• Yadav D
• Lee MY
• Kim JY
• Ryu H
• Huh JH
• Bae KS
• Ahn SV
• Chung CH
• Park JT
• Koh SB

• KMID: 2419082
• DOI: http://doi.org/10.3349/ymj.2017.58.4.763

Abstract

PURPOSE
Although γ-glutamyltransferase (GGT) is well known to be associated with metabolic syndrome (MS), prospective data on baseline and longitudinal changes in GGT levels and incident cases of MS are limited. We aimed to examine prospective associations between changes in GGT levels over time, as well as at baseline, and incident MS in Korean adults.
MATERIALS AND METHODS
A total of 2579 Korean adults free of MS were followed up for 2.6 years. Data were collected from 2005-2008 (baseline) and from 2008-2011 (follow-up). Serum GGT levels were determined by enzymatic methods.
RESULTS
During follow-up, 558 participants (21.6%) developed MS. A gradual increase in the incidence of MS was observed across GGT quartiles. After adjustment for confounding factors, the odds ratio and 95% confidence interval (CI) for new onset MS, comparing the highest to the lowest quartiles of baseline GGT, was 2.07 (95% CI: 1.52-2.80). The odds ratio for the highest GGT changes (>4 IU/L increase) in comparison to the lowest GGT changes (<-5 IU/L decrease) was 1.75 (95% CI: 1.32-2.33). Among participants with baseline GGT concentrations CONCLUSION
High initial GGT concentration and increases in GGT concentration over time should be considered independent predictors of and to have a combined effect on incident MS.

Keyword

γ-glutamyltransferase; cohort; metabolic syndrome

MeSH Terms

Atherosclerosis/epidemiology
Female
Humans
Incidence
Longitudinal Studies
Male
Metabolic Syndrome/*blood/*enzymology/epidemiology
Middle Aged
Odds Ratio
Prospective Studies
Republic of Korea/epidemiology
Risk Factors
Rural Population
gamma-Glutamyltransferase/*blood
gamma-Glutamyltransferase

Figure

• 

  Fig. 1 Description of the study population. KoGES-ARIRANG, Korean Genome and Epidemiology Study on Atherosclerosis Risk of Rural Areas in the Korean General Population.

• 

  Fig. 2 Incidence of each component of metabolic syndrome and metabolic syndrome per se by GGT quartile. GGT, γ-glutamyltransferase; BP, blood pressure; HDL, high density lipoprotein.

Reference

1. Emdin M, Pompella A, Paolicchi A. Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation. 2005; 112:2078–2080. PMID: 16203922.

2. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001; 38:263–355. PMID: 11563810.

3. Lee DH, Ha MH, Kim JH, Christiani DC, Gross MD, Steffes M, et al. Gamma-glutamyltransferase and diabetes--a 4 year follow-up study. Diabetologia. 2003; 46:359–364. PMID: 12687334.

4. Lee DH, Jacobs DR Jr, Gross M, Kiefe CI, Roseman J, Lewis CE, et al. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem. 2003; 49:1358–1366. PMID: 12881453.

5. Kim NH, Huh JK, Kim BJ, Kim MW, Kim BS, Kang JH. Serum gamma-glutamyl transferase level is an independent predictor of incident hypertension in Korean adults. Clin Exp Hypertens. 2012; 34:402–409. PMID: 22471622.

6. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007; 27:127–133. PMID: 17095717.

7. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Vorarlberg Health Monitoring and Promotion Program Study Group. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation. 2005; 112:2130–2137. PMID: 16186419.

8. Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol. 1995; 142:699–708. PMID: 7572939.

9. Abete I, Goyenechea E, Zulet MA, Martínez JA. Obesity and metabolic syndrome: potential benefit from specific nutritional components. Nutr Metab Cardiovasc Dis. 2011; 21(Suppl 2):B1–B15. PMID: 21764273.

10. Roberts CK, Barnard RJ, Sindhu RK, Jurczak M, Ehdaie A, Vaziri ND. Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome. Metabolism. 2006; 55:928–934. PMID: 16784966.

11. Lee DH, Blomhoff R, Jacobs DR Jr. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res. 2004; 38:535–539. PMID: 15346644.

12. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet. 2008; 371:1927–1935. PMID: 18501419.

13. Scott R, Donoghoe M, Watts GF, O'Brien R, Pardy C, Taskinen MR, et al. Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovasc Diabetol. 2011; 10:102. PMID: 22104275.

14. Lee MY, Koh SB, Koh JH, Nam SM, Shin JY, Shin YG, et al. Relationship between gamma-glutamyltransferase and metabolic syndrome in a Korean population. Diabet Med. 2008; 25:469–475. PMID: 18346161.

15. Kim JY, Ahn SV, Yoon JH, Koh SB, Yoon J, Yoo BS, et al. Prospective study of serum adiponectin and incident metabolic syndrome: the ARIRANG study. Diabetes Care. 2013; 36:1547–1553. PMID: 23275369.

16. Kawamoto R, Kohara K, Tabara Y, Miki T, Otsuka N. Serum gamma-glutamyl transferase levels are associated with metabolic syndrome in community-dwelling individuals. J Atheroscler Thromb. 2009; 16:355–362. PMID: 19755788.

17. Liu CF, Zhou WN, Fang NY. Gamma-glutamyltransferase levels and risk of metabolic syndrome: a meta-analysis of prospective cohort studies. Int J Clin Pract. 2012; 66:692–698. PMID: 22698421.

18. Ryu S, Chang Y, Woo HY, Yoo SH, Choi NK, Lee WY, et al. Longitudinal increase in gamma-glutamyltransferase within the reference interval predicts metabolic syndrome in middle-aged Korean men. Metabolism. 2010; 59:683–689. PMID: 19922966.

19. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr. 2004; 79:379–384. PMID: 14985210.

20. Bener A, Yousafzai MT, Darwish S, Al-Hamaq AO, Nasralla EA, Abdul-Ghani M. Obesity index that better predict metabolic syndrome: body mass index, waist circumference, waist hip ratio, or waist height ratio. J Obes. 2013; 2013:269038. PMID: 24000310.

21. Wei M, Gaskill SP, Haffner SM, Stern MP. Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans--a 7-year prospective study. Obes Res. 1997; 5:16–23. PMID: 9061711.

22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412–419. PMID: 3899825.

23. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120:1640–1645. PMID: 19805654.

24. Lee SY, Park HS, Kim DJ, Han JH, Kim SM, Cho GJ, et al. Appropriate waist circumference cutoff points for central obesity in Korean adults. Diabetes Res Clin Pract. 2007; 75:72–80. PMID: 16735075.

25. Suh BS. The association between serum gamma-glutamyltransferase within normal levels and metabolic syndrome in office workers: a 4-year follow-up Study. Korean J Fam Med. 2012; 33:51–58. PMID: 22745888.

26. Kugelman A, Choy HA, Liu R, Shi MM, Gozal E, Forman HJ. gamma-Glutamyl transpeptidase is increased by oxidative stress in rat alveolar L2 epithelial cells. Am J Respir Cell Mol Biol. 1994; 11:586–592. PMID: 7946387.

27. Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2004; 27:1427–1432. PMID: 15161799.

28. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004; 114:1752–1761. PMID: 15599400.

29. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004; 24:816–823. PMID: 14976002.

30. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001; 50:1844–1850. PMID: 11473047.

31. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002; 35:373–379. PMID: 11826411.

32. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004; 109:2818–2825. PMID: 15197153.

33. Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2005; 25:193–197. PMID: 15499043.

34. Lim S, Shin H, Song JH, Kwak SH, Kang SM, Yoon JW, et al. Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. Diabetes Care. 2011; 34:1323–1328. PMID: 21505206.